Artificial intelligence firm Paige has joined forces with Ohio State University Wexner Medical Center and its associated community hospitals in a collaborative effort to investigate the efficacy of AI-driven tools in cancer diagnosis.
Under this partnership, Wexner Medical Center will leverage Paige's FDA-approved AI-powered pathology algorithm, known as the Paige Prostate Suite, to assess the impact of AI integration on the identification of changes in prostate cancer diagnoses. This comprehensive study, encompassing multiple aspects of clinical application and health economics, aims to shed light on the potential for AI tools to enhance the precision, efficiency, and cost-effectiveness of cancer diagnosis within the context of community hospitals.
With a proven track record in advancing prostate cancer detection, the Paige Prostate Suite will be subjected to rigorous scrutiny to ascertain its contributions to the capabilities of general surgical pathologists in detecting, grading, and quantifying prostate cancers. The research will encompass various elements, including patient care pathways, specialist accessibility, and the level of confidence exhibited in conventional and AI-assisted diagnostic approaches. This collaborative endeavor was detailed in a press release by Paige on August 17th.
Click here to read the original news story.